nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—RET—autonomic nervous system—conduct disorder	0.0799	0.141	CbGeAlD
Ruxolitinib—PRKG2—brain—conduct disorder	0.0211	0.0374	CbGeAlD
Ruxolitinib—GRK1—brain—conduct disorder	0.0202	0.0357	CbGeAlD
Ruxolitinib—PRKCE—brain—conduct disorder	0.0197	0.0349	CbGeAlD
Ruxolitinib—PLK1—brain—conduct disorder	0.019	0.0335	CbGeAlD
Ruxolitinib—RPS6KA6—brain—conduct disorder	0.019	0.0335	CbGeAlD
Ruxolitinib—MAST1—brain—conduct disorder	0.019	0.0335	CbGeAlD
Ruxolitinib—DCLK3—brain—conduct disorder	0.018	0.0318	CbGeAlD
Ruxolitinib—PLK3—brain—conduct disorder	0.0158	0.028	CbGeAlD
Ruxolitinib—LTK—brain—conduct disorder	0.0153	0.027	CbGeAlD
Ruxolitinib—CAMK1—brain—conduct disorder	0.0148	0.0262	CbGeAlD
Ruxolitinib—MARK2—brain—conduct disorder	0.0144	0.0254	CbGeAlD
Ruxolitinib—TAOK2—brain—conduct disorder	0.0133	0.0235	CbGeAlD
Ruxolitinib—JAK3—brain—conduct disorder	0.0122	0.0216	CbGeAlD
Ruxolitinib—JAK1—brain—conduct disorder	0.0121	0.0215	CbGeAlD
Ruxolitinib—DCLK1—brain—conduct disorder	0.0121	0.0215	CbGeAlD
Ruxolitinib—PLK4—brain—conduct disorder	0.0121	0.0213	CbGeAlD
Ruxolitinib—CAMK1D—brain—conduct disorder	0.0118	0.021	CbGeAlD
Ruxolitinib—PHKG2—brain—conduct disorder	0.0118	0.0208	CbGeAlD
Ruxolitinib—DAPK2—brain—conduct disorder	0.0116	0.0205	CbGeAlD
Ruxolitinib—STK16—brain—conduct disorder	0.0114	0.0202	CbGeAlD
Ruxolitinib—HIPK2—brain—conduct disorder	0.0113	0.0201	CbGeAlD
Ruxolitinib—MAP3K19—brain—conduct disorder	0.0111	0.0196	CbGeAlD
Ruxolitinib—DAPK3—brain—conduct disorder	0.0109	0.0193	CbGeAlD
Ruxolitinib—CLK2—brain—conduct disorder	0.0108	0.0191	CbGeAlD
Ruxolitinib—ROCK1—brain—conduct disorder	0.0105	0.0185	CbGeAlD
Ruxolitinib—DYRK1A—brain—conduct disorder	0.0102	0.018	CbGeAlD
Ruxolitinib—BMPR2—brain—conduct disorder	0.0102	0.018	CbGeAlD
Ruxolitinib—NUAK2—brain—conduct disorder	0.0097	0.0172	CbGeAlD
Ruxolitinib—BMP2K—brain—conduct disorder	0.00909	0.0161	CbGeAlD
Ruxolitinib—CAMK2G—brain—conduct disorder	0.00909	0.0161	CbGeAlD
Ruxolitinib—LRRK2—brain—conduct disorder	0.00901	0.0159	CbGeAlD
Ruxolitinib—MAP3K2—brain—conduct disorder	0.00825	0.0146	CbGeAlD
Ruxolitinib—MAP3K7—brain—conduct disorder	0.00817	0.0145	CbGeAlD
Ruxolitinib—TYK2—brain—conduct disorder	0.00803	0.0142	CbGeAlD
Ruxolitinib—MKNK2—brain—conduct disorder	0.00792	0.014	CbGeAlD
Ruxolitinib—IRAK1—brain—conduct disorder	0.00792	0.014	CbGeAlD
Ruxolitinib—RET—brain—conduct disorder	0.00773	0.0137	CbGeAlD
Ruxolitinib—JAK2—brain—conduct disorder	0.0073	0.0129	CbGeAlD
Ruxolitinib—MAP3K3—brain—conduct disorder	0.00704	0.0125	CbGeAlD
Ruxolitinib—TAOK3—brain—conduct disorder	0.00642	0.0114	CbGeAlD
Ruxolitinib—HIPK2—C-MYB transcription factor network—EP300—conduct disorder	0.00366	0.00841	CbGpPWpGaD
Ruxolitinib—RET—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00358	0.00823	CbGpPWpGaD
Ruxolitinib—CAMK2G—Cellular response to heat stress—EP300—conduct disorder	0.00349	0.00802	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by VEGF—WASF1—conduct disorder	0.00349	0.00801	CbGpPWpGaD
Ruxolitinib—PLK3—Direct p53 effectors—EP300—conduct disorder	0.00345	0.00793	CbGpPWpGaD
Ruxolitinib—CAMK2G—Neuronal System—GABRA2—conduct disorder	0.00343	0.00789	CbGpPWpGaD
Ruxolitinib—PLK1—FoxO family signaling—EP300—conduct disorder	0.00341	0.00784	CbGpPWpGaD
Ruxolitinib—PLK3—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.00325	0.00747	CbGpPWpGaD
Ruxolitinib—RPS6KA6—Neuronal System—COMT—conduct disorder	0.00316	0.00727	CbGpPWpGaD
Ruxolitinib—CAMK2G—IFN-gamma pathway—EP300—conduct disorder	0.00316	0.00727	CbGpPWpGaD
Ruxolitinib—PLK1—Validated transcriptional targets of TAp63 isoforms—EP300—conduct disorder	0.00316	0.00726	CbGpPWpGaD
Ruxolitinib—RPS6KA6—Neuronal System—MAOA—conduct disorder	0.00314	0.00722	CbGpPWpGaD
Ruxolitinib—LRRK2—Wnt Signaling Pathway and Pluripotency—EP300—conduct disorder	0.00313	0.0072	CbGpPWpGaD
Ruxolitinib—RET—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00292	0.00671	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—MB21D1—conduct disorder	0.0029	0.00666	CbGpPWpGaD
Ruxolitinib—PRKCE—Role of Calcineurin-dependent NFAT signaling in lymphocytes—EP300—conduct disorder	0.00288	0.00661	CbGpPWpGaD
Ruxolitinib—JAK2—VEGFA-VEGFR2 Pathway—WASF1—conduct disorder	0.0028	0.00643	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by VEGF—WASF1—conduct disorder	0.00264	0.00607	CbGpPWpGaD
Ruxolitinib—JAK1—IFN-gamma pathway—EP300—conduct disorder	0.0025	0.00576	CbGpPWpGaD
Ruxolitinib—JAK3—IL-4 Signaling Pathway—EP300—conduct disorder	0.00243	0.00558	CbGpPWpGaD
Ruxolitinib—PLK1—p73 transcription factor network—EP300—conduct disorder	0.00233	0.00535	CbGpPWpGaD
Ruxolitinib—HIPK2—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.00229	0.00526	CbGpPWpGaD
Ruxolitinib—HIPK2—Gene Expression—POLR3A—conduct disorder	0.00223	0.00513	CbGpPWpGaD
Ruxolitinib—CAMK2G—Transmission across Chemical Synapses—COMT—conduct disorder	0.00215	0.00495	CbGpPWpGaD
Ruxolitinib—CAMK2G—Transmission across Chemical Synapses—MAOA—conduct disorder	0.00214	0.00492	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—POLR3A—conduct disorder	0.00213	0.00489	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—MB21D1—conduct disorder	0.0021	0.00483	CbGpPWpGaD
Ruxolitinib—JAK1—TGF-beta Receptor Signaling—EP300—conduct disorder	0.00209	0.0048	CbGpPWpGaD
Ruxolitinib—JAK1—IL-4 Signaling Pathway—EP300—conduct disorder	0.00209	0.0048	CbGpPWpGaD
Ruxolitinib—PRKCE—G alpha (q) signalling events—HTR2A—conduct disorder	0.00201	0.00462	CbGpPWpGaD
Ruxolitinib—BMPR2—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.00195	0.00447	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle—EP300—conduct disorder	0.0019	0.00436	CbGpPWpGaD
Ruxolitinib—CYP3A4—Estrogen metabolism—COMT—conduct disorder	0.00185	0.00426	CbGpPWpGaD
Ruxolitinib—PRKG2—Metabolism—CGA—conduct disorder	0.00182	0.00419	CbGpPWpGaD
Ruxolitinib—PRKG2—Circadian rythm related genes—EP300—conduct disorder	0.00182	0.00418	CbGpPWpGaD
Ruxolitinib—PRKCE—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.0018	0.00413	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—WASF1—conduct disorder	0.00179	0.00411	CbGpPWpGaD
Ruxolitinib—PLK1—G2/M Transition—EP300—conduct disorder	0.00175	0.00402	CbGpPWpGaD
Ruxolitinib—PRKCE—Wnt Signaling Pathway and Pluripotency—EP300—conduct disorder	0.00173	0.00397	CbGpPWpGaD
Ruxolitinib—PLK1—Mitotic G2-G2/M phases—EP300—conduct disorder	0.00172	0.00396	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—MB21D1—conduct disorder	0.00169	0.00388	CbGpPWpGaD
Ruxolitinib—CAMK2G—Neuronal System—COMT—conduct disorder	0.00165	0.0038	CbGpPWpGaD
Ruxolitinib—CAMK2G—Neuronal System—MAOA—conduct disorder	0.00164	0.00377	CbGpPWpGaD
Ruxolitinib—PLK4—G2/M Transition—EP300—conduct disorder	0.00163	0.00375	CbGpPWpGaD
Ruxolitinib—PLK4—Mitotic G2-G2/M phases—EP300—conduct disorder	0.00161	0.0037	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—MB21D1—conduct disorder	0.0016	0.00368	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—CGA—conduct disorder	0.00157	0.0036	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—MB21D1—conduct disorder	0.00155	0.00357	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—CGA—conduct disorder	0.00155	0.00356	CbGpPWpGaD
Ruxolitinib—DYRK1A—Circadian rythm related genes—EP300—conduct disorder	0.00155	0.00356	CbGpPWpGaD
Ruxolitinib—RET—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00155	0.00355	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—MB21D1—conduct disorder	0.00155	0.00355	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—POLR3A—conduct disorder	0.00154	0.00355	CbGpPWpGaD
Ruxolitinib—TYK2—IL-4 Signaling Pathway—EP300—conduct disorder	0.00154	0.00354	CbGpPWpGaD
Ruxolitinib—JAK1—p73 transcription factor network—EP300—conduct disorder	0.00154	0.00354	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—CGA—conduct disorder	0.00152	0.0035	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—MB21D1—conduct disorder	0.00151	0.00347	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—MB21D1—conduct disorder	0.00151	0.00346	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—CGA—conduct disorder	0.00143	0.00329	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—MB21D1—conduct disorder	0.00142	0.00327	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—CGA—conduct disorder	0.00142	0.00327	CbGpPWpGaD
Ruxolitinib—JAK2—IFN-gamma pathway—EP300—conduct disorder	0.0014	0.00322	CbGpPWpGaD
Ruxolitinib—PLK1—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.00139	0.00319	CbGpPWpGaD
Ruxolitinib—ROCK1—Androgen receptor signaling pathway—EP300—conduct disorder	0.00138	0.00317	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—CGA—conduct disorder	0.00132	0.00304	CbGpPWpGaD
Ruxolitinib—JAK2—Notch-mediated HES/HEY network—EP300—conduct disorder	0.00131	0.003	CbGpPWpGaD
Ruxolitinib—JAK1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.0013	0.003	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—WASF1—conduct disorder	0.0013	0.00299	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—CGA—conduct disorder	0.00129	0.00298	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling by Wnt—EP300—conduct disorder	0.00126	0.00291	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—POLR3A—conduct disorder	0.00124	0.00285	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—MB21D1—conduct disorder	0.00122	0.00282	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—WASF1—conduct disorder	0.00122	0.00281	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—CGA—conduct disorder	0.0012	0.00276	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—MB21D1—conduct disorder	0.00118	0.0027	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—POLR3A—conduct disorder	0.00117	0.0027	CbGpPWpGaD
Ruxolitinib—JAK2—IL-4 Signaling Pathway—EP300—conduct disorder	0.00117	0.00269	CbGpPWpGaD
Ruxolitinib—PLK1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.00115	0.00264	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—WASF1—conduct disorder	0.00115	0.00264	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—POLR3A—conduct disorder	0.00114	0.00262	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—CGA—conduct disorder	0.00114	0.00262	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—POLR3A—conduct disorder	0.00113	0.00261	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—CGA—conduct disorder	0.00112	0.00257	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—POLR3A—conduct disorder	0.00111	0.00255	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—POLR3A—conduct disorder	0.00111	0.00254	CbGpPWpGaD
Ruxolitinib—JAK2—Kit receptor signaling pathway—EP300—conduct disorder	0.00109	0.0025	CbGpPWpGaD
Ruxolitinib—JAK2—Notch Signaling Pathway—EP300—conduct disorder	0.00106	0.00244	CbGpPWpGaD
Ruxolitinib—MAP3K7—C-MYB transcription factor network—EP300—conduct disorder	0.00105	0.00241	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—POLR3A—conduct disorder	0.00104	0.0024	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—WASF1—conduct disorder	0.00104	0.0024	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—WASF1—conduct disorder	0.00104	0.00239	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—CGA—conduct disorder	0.00103	0.00238	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—CGA—conduct disorder	0.00102	0.00234	CbGpPWpGaD
Ruxolitinib—ROCK1—TGF-beta Signaling Pathway—EP300—conduct disorder	0.001	0.00231	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—WASF1—conduct disorder	0.000988	0.00227	CbGpPWpGaD
Ruxolitinib—TYK2—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000963	0.00221	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—WASF1—conduct disorder	0.000959	0.0022	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—WASF1—conduct disorder	0.000955	0.00219	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—WASF1—conduct disorder	0.000932	0.00214	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MB21D1—conduct disorder	0.000931	0.00214	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—WASF1—conduct disorder	0.00093	0.00214	CbGpPWpGaD
Ruxolitinib—JAK1—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.000917	0.00211	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MB21D1—conduct disorder	0.000904	0.00208	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—POLR3A—conduct disorder	0.000899	0.00207	CbGpPWpGaD
Ruxolitinib—MAP3K7—Wnt Signaling Pathway and Pluripotency—EP300—conduct disorder	0.000899	0.00207	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—WASF1—conduct disorder	0.00088	0.00202	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—DRD4—conduct disorder	0.000878	0.00202	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MB21D1—conduct disorder	0.000877	0.00202	CbGpPWpGaD
Ruxolitinib—PRKG2—Hemostasis—EP300—conduct disorder	0.00087	0.002	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—POLR3A—conduct disorder	0.000863	0.00199	CbGpPWpGaD
Ruxolitinib—RPS6KA6—Developmental Biology—EP300—conduct disorder	0.000859	0.00197	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—DRD4—conduct disorder	0.000853	0.00196	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CGA—conduct disorder	0.000841	0.00193	CbGpPWpGaD
Ruxolitinib—PRKG2—Metabolism—COMT—conduct disorder	0.000822	0.00189	CbGpPWpGaD
Ruxolitinib—PRKG2—Metabolism—MAOA—conduct disorder	0.000816	0.00188	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—DRD4—conduct disorder	0.000802	0.00184	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—DRD4—conduct disorder	0.000797	0.00183	CbGpPWpGaD
Ruxolitinib—DYRK1A—Cell Cycle, Mitotic—EP300—conduct disorder	0.00078	0.00179	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—CGA—conduct disorder	0.000763	0.00175	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—WASF1—conduct disorder	0.000757	0.00174	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—DRD4—conduct disorder	0.000741	0.0017	CbGpPWpGaD
Ruxolitinib—CAMK2G—Cellular responses to stress—EP300—conduct disorder	0.00074	0.0017	CbGpPWpGaD
Ruxolitinib—MAP3K7—TGF-beta Signaling Pathway—EP300—conduct disorder	0.000731	0.00168	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00073	0.00168	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—WASF1—conduct disorder	0.000727	0.00167	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—DRD4—conduct disorder	0.000725	0.00167	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CGA—conduct disorder	0.00071	0.00163	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—COMT—conduct disorder	0.000699	0.00161	CbGpPWpGaD
Ruxolitinib—DYRK1A—Cell Cycle—EP300—conduct disorder	0.000698	0.0016	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—MAOA—conduct disorder	0.000694	0.0016	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MB21D1—conduct disorder	0.000685	0.00158	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—POLR3A—conduct disorder	0.000684	0.00157	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—WASF1—conduct disorder	0.000674	0.00155	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—DRD4—conduct disorder	0.000673	0.00155	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—POLR3A—conduct disorder	0.000664	0.00153	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—POLR3A—conduct disorder	0.000644	0.00148	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—DRD4—conduct disorder	0.000637	0.00146	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CGA—conduct disorder	0.000637	0.00146	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—DRD4—conduct disorder	0.000627	0.00144	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CGA—conduct disorder	0.00061	0.0014	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CGA—conduct disorder	0.0006	0.00138	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—DRD4—conduct disorder	0.000579	0.00133	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CGA—conduct disorder	0.000578	0.00133	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—WASF1—conduct disorder	0.000575	0.00132	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—HTR2A—conduct disorder	0.000573	0.00132	CbGpPWpGaD
Ruxolitinib—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00057	0.00131	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—DRD4—conduct disorder	0.000569	0.00131	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—WASF1—conduct disorder	0.000569	0.00131	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—WASF1—conduct disorder	0.000559	0.00128	CbGpPWpGaD
Ruxolitinib—JAK2—Factors involved in megakaryocyte development and platelet production—EP300—conduct disorder	0.000558	0.00128	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—HTR2A—conduct disorder	0.000556	0.00128	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle, Mitotic—EP300—conduct disorder	0.000556	0.00128	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—WASF1—conduct disorder	0.000542	0.00125	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—HTR2A—conduct disorder	0.000523	0.0012	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—HTR2A—conduct disorder	0.00052	0.0012	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle, Mitotic—EP300—conduct disorder	0.000519	0.00119	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—POLR3A—conduct disorder	0.000503	0.00116	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle—EP300—conduct disorder	0.000497	0.00114	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—WASF1—conduct disorder	0.000489	0.00112	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—HTR2A—conduct disorder	0.000483	0.00111	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—WASF1—conduct disorder	0.000481	0.00111	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—EP300—conduct disorder	0.00048	0.0011	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—HTR2A—conduct disorder	0.000473	0.00109	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—DRD4—conduct disorder	0.000471	0.00108	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CGA—conduct disorder	0.000464	0.00107	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle—EP300—conduct disorder	0.000464	0.00107	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CGA—conduct disorder	0.000451	0.00104	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—HTR2A—conduct disorder	0.000439	0.00101	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CGA—conduct disorder	0.000437	0.001	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—EP300—conduct disorder	0.000432	0.000994	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—DRD4—conduct disorder	0.000427	0.000982	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—WASF1—conduct disorder	0.000423	0.000973	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—HTR2A—conduct disorder	0.000416	0.000956	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—HTR2A—conduct disorder	0.000409	0.00094	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—EP300—conduct disorder	0.000405	0.000931	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—DRD4—conduct disorder	0.000397	0.000914	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—EP300—conduct disorder	0.000396	0.00091	CbGpPWpGaD
Ruxolitinib—JAK2—Chromatin modifying enzymes—EP300—conduct disorder	0.000384	0.000883	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HTR2A—conduct disorder	0.000378	0.000868	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—WASF1—conduct disorder	0.000372	0.000855	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HTR2A—conduct disorder	0.000371	0.000854	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling by Wnt—EP300—conduct disorder	0.000363	0.000834	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—WASF1—conduct disorder	0.000361	0.00083	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—EP300—conduct disorder	0.000358	0.000823	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—DRD4—conduct disorder	0.000357	0.00082	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—EP300—conduct disorder	0.000355	0.000817	CbGpPWpGaD
Ruxolitinib—PRKG2—Metabolism—EP300—conduct disorder	0.000353	0.000811	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—WASF1—conduct disorder	0.00035	0.000805	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—EP300—conduct disorder	0.000349	0.000803	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—EP300—conduct disorder	0.000349	0.000801	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—DRD4—conduct disorder	0.000342	0.000786	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CGA—conduct disorder	0.000341	0.000785	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—DRD4—conduct disorder	0.000336	0.000773	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—DRD4—conduct disorder	0.000324	0.000744	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—EP300—conduct disorder	0.000314	0.000721	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HTR2A—conduct disorder	0.000307	0.000706	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—COMT—conduct disorder	0.000305	0.0007	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.000303	0.000696	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.0003	0.000691	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—EP300—conduct disorder	0.0003	0.000689	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—EP300—conduct disorder	0.000295	0.000678	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HTR2A—conduct disorder	0.000279	0.000641	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—EP300—conduct disorder	0.000277	0.000637	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—WASF1—conduct disorder	0.000274	0.000629	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—EP300—conduct disorder	0.000262	0.000603	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—DRD4—conduct disorder	0.00026	0.000598	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HTR2A—conduct disorder	0.000259	0.000596	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—DRD4—conduct disorder	0.000252	0.00058	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—EP300—conduct disorder	0.000252	0.000579	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—EP300—conduct disorder	0.000251	0.000576	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—DRD4—conduct disorder	0.000245	0.000563	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—EP300—conduct disorder	0.000239	0.000549	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—HTR2A—conduct disorder	0.000233	0.000535	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—EP300—conduct disorder	0.000232	0.000534	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—EP300—conduct disorder	0.000232	0.000533	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—EP300—conduct disorder	0.000231	0.00053	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—EP300—conduct disorder	0.000225	0.000518	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—EP300—conduct disorder	0.000225	0.000517	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HTR2A—conduct disorder	0.000223	0.000513	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HTR2A—conduct disorder	0.000219	0.000504	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—EP300—conduct disorder	0.000212	0.000488	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HTR2A—conduct disorder	0.000211	0.000486	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—EP300—conduct disorder	0.000199	0.000457	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—EP300—conduct disorder	0.000195	0.000448	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—DRD4—conduct disorder	0.000191	0.00044	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EP300—conduct disorder	0.000183	0.00042	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EP300—conduct disorder	0.000176	0.000404	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HTR2A—conduct disorder	0.00017	0.00039	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EP300—conduct disorder	0.000169	0.000388	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HTR2A—conduct disorder	0.000165	0.000379	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EP300—conduct disorder	0.000163	0.000374	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HTR2A—conduct disorder	0.00016	0.000367	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EP300—conduct disorder	0.000139	0.00032	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EP300—conduct disorder	0.000137	0.000316	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EP300—conduct disorder	0.000135	0.00031	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EP300—conduct disorder	0.000131	0.000301	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HTR2A—conduct disorder	0.000125	0.000287	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EP300—conduct disorder	0.000125	0.000286	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EP300—conduct disorder	0.000118	0.000272	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EP300—conduct disorder	0.000116	0.000267	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CGA—conduct disorder	0.000115	0.000265	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EP300—conduct disorder	0.000102	0.000235	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EP300—conduct disorder	9.44e-05	0.000217	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EP300—conduct disorder	8.99e-05	0.000207	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EP300—conduct disorder	8.72e-05	0.000201	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EP300—conduct disorder	8.46e-05	0.000195	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EP300—conduct disorder	6.61e-05	0.000152	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—COMT—conduct disorder	5.21e-05	0.00012	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MAOA—conduct disorder	5.17e-05	0.000119	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—EP300—conduct disorder	2.23e-05	5.14e-05	CbGpPWpGaD
